This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fraunhofer-Gesellschaft Zur Förderung Der Angewandten Forschung E.v.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Innovations by Sandra Sarembe in Antibiotic Release Technology
Introduction
Sandra Sarembe is an accomplished inventor based in Halle, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release systems for antibiotics. Her innovative work focuses on enhancing the efficacy and longevity of tetracycline antibiotics.
Latest Patents
Sandra holds a patent for her invention titled "Tetracycline complexes with sustained activity." This invention relates to the controlled release of tetracycline antibiotics. Specifically, it involves a complex comprising a tetracycline compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, combined with a divalent metal carboxylate. The patent outlines a pharmaceutical preparation that includes this complex, methods for manufacturing it, and its application in treating bacterial infections. The invention aims to maintain antibiotic activity over an extended period, particularly for the therapy and prophylaxis of acute, chronic, or recurrent periodontal diseases. She has 1 patent to her name.
Career Highlights
Throughout her career, Sandra has worked with notable organizations, including the Fraunhofer Society for the Advancement of Applied Research. Her work at these institutions has allowed her to focus on innovative research and development in the pharmaceutical sector.
Collaborations
Sandra has collaborated with esteemed colleagues such as Andreas Kiesow and Martin Kirchberg. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Sandra Sarembe's contributions to antibiotic technology through her innovative patent demonstrate her commitment to improving healthcare solutions. Her work continues to influence the field of pharmaceuticals and offers promising advancements in the treatment of bacterial infections.